Introduction – Company Background

GuangXin Industrial Co., Ltd. is a specialized manufacturer dedicated to the development and production of high-quality insoles.

With a strong foundation in material science and footwear ergonomics, we serve as a trusted partner for global brands seeking reliable insole solutions that combine comfort, functionality, and design.

With years of experience in insole production and OEM/ODM services, GuangXin has successfully supported a wide range of clients across various industries—including sportswear, health & wellness, orthopedic care, and daily footwear.

From initial prototyping to mass production, we provide comprehensive support tailored to each client’s market and application needs.

At GuangXin, we are committed to quality, innovation, and sustainable development. Every insole we produce reflects our dedication to precision craftsmanship, forward-thinking design, and ESG-driven practices.

By integrating eco-friendly materials, clean production processes, and responsible sourcing, we help our partners meet both market demand and environmental goals.

Core Strengths in Insole Manufacturing

At GuangXin Industrial, our core strength lies in our deep expertise and versatility in insole and pillow manufacturing. We specialize in working with a wide range of materials, including PU (polyurethane), natural latex, and advanced graphene composites, to develop insoles and pillows that meet diverse performance, comfort, and health-support needs.

Whether it's cushioning, support, breathability, or antibacterial function, we tailor material selection to the exact requirements of each project-whether for foot wellness or ergonomic sleep products.

We provide end-to-end manufacturing capabilities under one roof—covering every stage from material sourcing and foaming, to precision molding, lamination, cutting, sewing, and strict quality control. This full-process control not only ensures product consistency and durability, but also allows for faster lead times and better customization flexibility.

With our flexible production capacity, we accommodate both small batch custom orders and high-volume mass production with equal efficiency. Whether you're a startup launching your first insole or pillow line, or a global brand scaling up to meet market demand, GuangXin is equipped to deliver reliable OEM/ODM solutions that grow with your business.

Customization & OEM/ODM Flexibility

GuangXin offers exceptional flexibility in customization and OEM/ODM services, empowering our partners to create insole products that truly align with their brand identity and target market. We develop insoles tailored to specific foot shapes, end-user needs, and regional market preferences, ensuring optimal fit and functionality.

Our team supports comprehensive branding solutions, including logo printing, custom packaging, and product integration support for marketing campaigns. Whether you're launching a new product line or upgrading an existing one, we help your vision come to life with attention to detail and consistent brand presentation.

With fast prototyping services and efficient lead times, GuangXin helps reduce your time-to-market and respond quickly to evolving trends or seasonal demands. From concept to final production, we offer agile support that keeps you ahead of the competition.

Quality Assurance & Certifications

Quality is at the heart of everything we do. GuangXin implements a rigorous quality control system at every stage of production—ensuring that each insole meets the highest standards of consistency, comfort, and durability.

We provide a variety of in-house and third-party testing options, including antibacterial performance, odor control, durability testing, and eco-safety verification, to meet the specific needs of our clients and markets.

Our products are fully compliant with international safety and environmental standards, such as REACH, RoHS, and other applicable export regulations. This ensures seamless entry into global markets while supporting your ESG and product safety commitments.

ESG-Oriented Sustainable Production

At GuangXin Industrial, we are committed to integrating ESG (Environmental, Social, and Governance) values into every step of our manufacturing process. We actively pursue eco-conscious practices by utilizing eco-friendly materials and adopting low-carbon production methods to reduce environmental impact.

To support circular economy goals, we offer recycled and upcycled material options, including innovative applications such as recycled glass and repurposed LCD panel glass. These materials are processed using advanced techniques to retain performance while reducing waste—contributing to a more sustainable supply chain.

We also work closely with our partners to support their ESG compliance and sustainability reporting needs, providing documentation, traceability, and material data upon request. Whether you're aiming to meet corporate sustainability targets or align with global green regulations, GuangXin is your trusted manufacturing ally in building a better, greener future.

Let’s Build Your Next Insole Success Together

Looking for a reliable insole manufacturing partner that understands customization, quality, and flexibility? GuangXin Industrial Co., Ltd. specializes in high-performance insole production, offering tailored solutions for brands across the globe. Whether you're launching a new insole collection or expanding your existing product line, we provide OEM/ODM services built around your unique design and performance goals.

From small-batch custom orders to full-scale mass production, our flexible insole manufacturing capabilities adapt to your business needs. With expertise in PU, latex, and graphene insole materials, we turn ideas into functional, comfortable, and market-ready insoles that deliver value.

Contact us today to discuss your next insole project. Let GuangXin help you create custom insoles that stand out, perform better, and reflect your brand’s commitment to comfort, quality, and sustainability.

🔗 Learn more or get in touch:
🌐 Website: https://www.deryou-tw.com/
📧 Email: shela.a9119@msa.hinet.net
📘 Facebook: facebook.com/deryou.tw
📷 Instagram: instagram.com/deryou.tw

Custom graphene foam processing Indonesia

Are you looking for a trusted and experienced manufacturing partner that can bring your comfort-focused product ideas to life? GuangXin Industrial Co., Ltd. is your ideal OEM/ODM supplier, specializing in insole production, pillow manufacturing, and advanced graphene product design.

With decades of experience in insole OEM/ODM, we provide full-service manufacturing—from PU and latex to cutting-edge graphene-infused insoles—customized to meet your performance, support, and breathability requirements. Our production process is vertically integrated, covering everything from material sourcing and foaming to molding, cutting, and strict quality control.Graphene insole manufacturer in Vietnam

Beyond insoles, GuangXin also offers pillow OEM/ODM services with a focus on ergonomic comfort and functional innovation. Whether you need memory foam, latex, or smart material integration for neck and sleep support, we deliver tailor-made solutions that reflect your brand’s values.

We are especially proud to lead the way in ESG-driven insole development. Through the use of recycled materials—such as repurposed LCD glass—and low-carbon production processes, we help our partners meet sustainability goals without compromising product quality. Our ESG insole solutions are designed not only for comfort but also for compliance with global environmental standards.High-performance insole OEM Indonesia

At GuangXin, we don’t just manufacture products—we create long-term value for your brand. Whether you're developing your first product line or scaling up globally, our flexible production capabilities and collaborative approach will help you go further, faster.Private label insole and pillow OEM China

📩 Contact us today to learn how our insole OEM, pillow ODM, and graphene product design services can elevate your product offering—while aligning with the sustainability expectations of modern consumers.One-stop OEM/ODM manufacturing factory and solution provider

Artist’s impression of the ‘living blood vessel’, featuring the new material Credit: Designed by Ziyu Wang and illustrated by Ella Maru Studio This is the first time scientists have observed vessels form with such a close resemblance to the complicated structure of naturally occurring blood vessels. An international research collaboration headed by the University of Sydney has created technology that allows for the production of materials that mirror the structure of living blood vessels, with major implications for the future of surgery. Preclinical research showed that once the manufactured blood vessel was transplanted into mice, the body accepted it and new cells and tissue began to develop in the appropriate locations, thereby converting it into a “living blood vessel.” While others have attempted to create blood vessels with varying degrees of success in the past, senior author Professor Anthony Weiss from the Charles Perkins Centre noted that this is the first instance where scientists have observed the vessels develop with such a high degree of similarity to the complex structure of naturally occurring blood vessels. “Nature converts this manufactured tube over time to one that looks, behaves, and functions like a real blood vessel,” said Professor Weiss. “The technology’s ability to recreate the complex structure of biological tissues shows it has the potential to not only manufacture blood vessels to assist in surgery but also sets the scene for the future creation of other synthetic tissues such as heart valves.” Implications for Pediatric Surgery Co-author Dr. Christopher Breuer of the Center for Regenerative Medicine at Nationwide Children’s Hospital and the Wexner Medical Center in Columbus, USA said he is excited about the potential of the research for children. “Currently when kids suffer from an abnormal vessel, surgeons have no choice but to use synthetic vessels that function well for a short time but inevitably children need additional surgeries as they grow. This new technology provides the exciting foundation for the manufactured blood vessels that to continue to grow and develop over time.” The technology was pioneered by lead author and bioengineer Dr. Ziyu Wang from the University of Sydney’s Charles Perkins Centre as part of his Ph.D. He expanded on previous research by Dr. Suzanne Mithieux, who is also affiliated with the Charles Perkins Centre. Natural blood vessel walls are made up of concentric rings of elastin (a protein that provides vessels elasticity and the ability to stretch), much like nesting dolls. As a result, the rings are elastic, allowing blood vessels to change size in response to blood flow. This new technology means that, for the first time, these important concentric elastin rings can develop naturally within the walls of implanted tubes. Simplified and Efficient Manufacturing Unlike current manufacturing processes for synthetic materials used for surgery, which can be lengthy, complex, and expensive, this new manufacturing process is swift and well-defined. “These synthetic vessels are elegant because they are manufactured from just two naturally occurring materials that are well-tolerated by the body,” said Dr. Wang. “Tropoelastin (the natural building block for elastin) is packaged in an elastic sheath which dissipates gradually and promotes the formation of highly organized, natural mimics of functioning blood vessels.” The manufactured tube can also be safely stored in a sterile plastic bag until transplantation. Reference: “Rapid Regeneration of a Neoartery with Elastic Lamellae” by Ziyu Wang, Suzanne M. Mithieux, Howard Vindin, Yiwei Wang, Miao Zhang, Linyang Liu, Jacob Zbinden, Kevin M. Blum, Tai Yi, Yuichi Matsuzaki, Farshad Oveissi, Reyda Akdemir, Karen M. Lockley, Lingyue Zhang, Ke Ma, Juan Guan, Anna Waterhouse, Nguyen T. H. Pham, Brian S. Hawkett, Toshiharu Shinoka, Christopher K. Breuer and Anthony S. Weiss, 19 September 2022, Advanced Materials.  DOI: 10.1002/adma.202205614 Ethics approval was obtained from the Sydney Local Health District, Australia and Nationwide Children’s Hospital, USA. Professor Anthony Weiss is the founding scientist of Elastagen Pty.Ltd., now sold to Allergan, Inc., an AbbVie company. The authors declare no other competing interests.

Purified Photorhabdus virulence cassettes (PVCs), imaged using TEM. Credit: Joseph Kreitz, Broad Institute of MIT and Harvard, McGovern Institute for Brain Research at MIT Bacterial Injection System Delivers Proteins in Mice and Human Cells With further development, the programmable system could be used in a range of applications including gene therapy and cancer therapy. Researchers at the Broad Institute of MIT and Harvard and the McGovern Institute for Brain Research at MIT have harnessed a natural bacterial system to develop a new protein delivery approach that works in human cells and animals. The technology, described recently in the journal Nature, can be programmed to deliver a variety of proteins, including ones for gene editing, to different cell types. The system could potentially be a safe and efficient way to deliver gene therapies and cancer therapies. Led by Broad core institute member and McGovern Institute investigator Feng Zhang, the team took advantage of a tiny syringe-like injection structure, produced by a bacterium, that naturally binds to insect cells and injects a protein payload into them. The researchers used the artificial intelligence tool AlphaFold to engineer these syringe structures to deliver a range of useful proteins to both human cells and cells in live mice. Programmed Photorhabdus virulence cassettes bound to a cancer cell, imaged with transmission electron microscopy. Credit: Joseph Kreitz/Broad Institute, McGovern Institute “This is a really beautiful example of how protein engineering can alter the biological activity of a natural system,” said Joseph Kreitz, the study’s first author and a graduate student in Zhang’s lab. “I think it substantiates protein engineering as a useful tool in bioengineering and the development of new therapeutic systems.” “Delivery of therapeutic molecules is a major bottleneck for medicine, and we will need a deep bench of options to get these powerful new therapies into the right cells in the body,” added Zhang. “By learning from how nature transports proteins, we were able to develop a new platform that can help address this gap.” Zhang is senior author on the study and is also the James and Patricia Poitras Professor of Neuroscience at MIT and an investigator at the Howard Hughes Medical Institute. Injection via Contraction Symbiotic bacteria use the roughly 100-nanometer-long syringe-like machines to inject proteins into host cells to help adjust the biology of their surroundings and enhance their survival. These machines, called extracellular contractile injection systems (eCISs), consist of a rigid tube inside a sheath that contracts, driving a spike on the end of the tube through the cell membrane. This forces protein cargo inside the tube to enter the cell. On the outside of one end of the eCIS are tail fibers that recognize specific receptors on the cell surface and latch on. Previous research has shown that eCISs can naturally target insect and mouse cells, but Kreitz thought it might be possible to modify them to deliver proteins to human cells by reengineering the tail fibers to bind to different receptors. Cancer cells killed by programmed Photorhabdus virulence cassettes, imaged with a scanning electron microscope. Credit: Joseph Kreitz/Broad Institute, McGovern Institute Using AlphaFold, which predicts a protein’s structure from its amino acid sequence, the researchers redesigned tail fibers of an eCIS produced by Photorhabdus bacteria to bind to human cells. By reengineering another part of the complex, the scientists tricked the syringe into delivering a protein of their choosing, in some cases with remarkably high efficiency. The team made eCISs that targeted cancer cells expressing the EGF receptor and showed that they killed almost 100 percent of the cells, but did not affect cells without the receptor. Though efficiency depends in part on the receptor the system is designed to target, Kreitz says that the findings demonstrate the promise of the system with thoughtful engineering. The researchers also used an eCIS to deliver proteins to the brain in live mice — where it didn’t provoke a detectable immune response, suggesting that eCISs could one day be used to safely deliver gene therapies to humans. Packaging Proteins Kreitz says the eCIS system is versatile, and the team has already used it to deliver a range of cargos including base editor proteins (which can make single-letter changes to DNA), proteins that are toxic to cancer cells, and Cas9, a large DNA-cutting enzyme used in many gene editing systems. Photorhabdus virulence cassettes (green) binding to insect cells (blue) prior to injection of payload proteins. Credit: Joseph Kreitz/Broad Institute, McGovern Institute In the future, Kreitz says researchers could engineer other components of the eCIS system to tune other properties, or to deliver other cargos such as DNA or RNA. He also wants to better understand the function of these systems in nature. “We and others have shown that this type of system is incredibly diverse across the biosphere, but they are not very well characterized,” Kreitz said. “And we believe this type of system plays really important roles in biology that are yet to be explored.” Reference: “Programmable protein delivery with a bacterial contractile injection system” by Joseph Kreitz, Mirco J. Friedrich, Akash Guru, Blake Lash, Makoto Saito, Rhiannon K. Macrae and Feng Zhang, 29 March 2023, Nature. DOI: 10.1038/s41586-023-05870-7 This work was supported in part by the National Institutes of Health, Howard Hughes Medical Institute, Poitras Center for Psychiatric Disorders Research at MIT, Hock E. Tan and K. Lisa Yang Center for Autism Research at MIT, K. Lisa Yang and Hock E. Tan Molecular Therapeutics Center at MIT, K. Lisa Yang Brain-Body Center at MIT, Broad Institute Programmable Therapeutics Gift Donors, Pershing Square Foundation, W. Ackman, N. Oxman, J. and P. Poitras, BT Charitable Foundation, C. and L. Asness, the Phillips family, D. Cheng, and R. Metcalfe.

Image-enabled cell sorting identifies and isolates cells of interest out of a complex pool of cells at high speed. Credit: Tobias Wüstefeld BD and EMBL have developed BD CellView Image Technology, a flow cytometry advancement that enables detailed, image-based cell sorting at high speeds. This innovation allows for enhanced research and discovery in fields such as immunology and genomics, marking a significant leap from traditional biomarker-only methods. BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that a study conducted in collaboration with the European Molecular Biology Laboratory (EMBL) and published as the cover story of the January 21st issue of the journal, Science, profiles a new BD innovation in flow cytometry that adds fluorescence imaging and image-based decisioning to sort individual cells at exceptionally high speed, based on the visual details of each cell and not solely on the type or quantity of biomarkers that are present. The new technology has the potential to transform immunology, cell biology and genomics research and enable new cell-based therapeutic discovery. Revolutionizing Cell Sorting with Imaging Cell sorting through flow cytometry is a technique that enables scientists to identify and sort individual cells based on specific characteristics of each cell in order to study them in more detail, evaluate how each cell may react to a new drug or perform other single cell experiments. Traditionally, cell sorters operate through identification and quantification of certain biomarkers (e.g. proteins) on or within a cell. The new innovation from BD, known as BD CellView Image Technology, can capture multiple images of individual cells flowing through the system at a speed of 15,000 cells per second and also adds a previously impossible capability of sorting cells based on detailed microscopic image analysis of individual cells at this speed. Enhanced Capabilities of BD CellView Image Technology By adding imaging to the traditional biomarker identification and quantification, the new technology not only identifies if and how much of a biomarker is present in the cell, but also its location or how it is distributed within the cell. By imaging the distribution of biomarkers with this technology, researchers obtain detailed information about cells that was previously invisible in traditional flow cytometry experiments, which enables them to answer complex biological questions, such as how cells grow, function and interact, or to study exact locations of viruses or proteins within a cell, all at a highly accelerated pace. “This innovation has overcome the typical compromise between speed and precision of sorting individual cells,” said Tom Polen, chairman, CEO and president of BD. “This breakthrough essentially equates to a researcher looking into a microscope, identifying specific characteristics of a cell of interest, and based on what they see, sorting each individual cell for further analysis — all at a rate of nearly 1 million cells every minute. The technology can analyze more than 1,000 times the amount of data compared to traditional flow cytometry methods, and sort cells at a rate of 15,000 per second based on their images. BD was the first company to commercialize flow cytometry technology in the 1970s, and this is yet another example of our storied history of innovation and technical leadership in this space.” Schematic of image-enabled cell sorting, developed at BD Biosciences and road tested by EMBL. Credit: BD Biosciences Broad Implications for Biomedical Research The new technology fills a long-standing gap in biomedical research by enabling scientists to more rapidly view and isolate cells with specific, observable traits of interest, which can accelerate discovery research and unlock potential therapies or cures for disease in a broad range of fields such as virology and oncology. “This technology represents the culmination of more than a decade’s worth of work from a highly multidisciplinary team of optical, mechanical, electrical, biomedical and software engineers and scientists that aimed to provide researchers a differentiated and flexible capability for analyzing single cells,” said Eric Diebold, worldwide vice president of R&D for BD Biosciences and co-corresponding author of the paper. “We have just scratched the surface of the types of science that will be enabled with this new high-throughput image-based cell sorting technology, and we look forward to how BD and the scientific community at-large will leverage it to advance both basic research and the development of therapeutics.” In-depth Study Results and Future Applications In the study published in Science, researchers used BD CellView Image Technology to study regulators of the NF-?B (nuclear factor kappa light chain enhancer of activated B cells) pathway, a protein complex that plays an important role in cellular immunity and stress response. The EMBL team measured the activity in this pathway by tracking the location of RelA, a protein that moves from the cytoplasm into the nucleus of the cell upon activation. Using BD CellView Image Technology, the screen allowed them to identify several novel regulators of this important cellular pathway in a matter of hours, instead of days as would be required using conventional approaches. This result has broad implications for accelerating the pace of genomic research and therapeutic discovery. “For years, researchers have desired a system for cell sorting that would allow them to get a detailed picture of a cell’s inner workings and to isolate those with microscopic phenotypes of interest,” said Dr. Lars Steinmetz, senior scientist at EMBL, professor of genetics at Stanford University and co-corresponding author of the paper. “This is what BD CellView Image Technology achieves, defining a new standard in cell isolation and characterization. We are excited about applying this technology to high-resolution genomic screening aimed at collecting functional information for every part of the genome. We are also exploring applications for cell-based diagnostics and characterization of cells in health and disease.” Reference: “Completing a genome-wide screen in less than nine hours” by Daniel Schraivogel, Terra M. Kuhn, Benedikt Rauscher, Marta Rodríguez-Martínez, Malte Paulsen, Keegan Owsley, Aaron Middlebrook, Christian Tischer, Beáta Ramasz, Diana Ordoñez-Rueda, Martina Dees, Sara Cuylen-Haering, Eric Diebold and Lars M. Steinmetz, 20 January 2022, Science. DOI: 10.1126/science.abj3013

DVDV1551RTWW78V